Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Revisiting a Meta-analysis Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19 patients
Lounnas e al., Archives of Microbiology & Immunology, doi: (meta analysis)
Lounnas, Revisiting a Meta-analysis Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19.., e al., Archives of Microbiology & Immunology, doi: (meta analysis)
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Analysis of the Fiolet meta analysis and correction of bias evaluation, showing HCQ RR 0.45 [0.31-0.59], and HCQ+AZ RR 0.34 [0.06-0.61].
Currently there are 36 HCQ early treatment studies and meta analysis shows:
OutcomeImprovement
Mortality72% lower [57‑81%]
Ventilation67% lower [-710‑99%]
ICU admission28% lower [-17‑55%]
Hospitalization41% lower [28‑52%]
Lounnas et al., 9 Feb 2021, peer-reviewed, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Arch Microbiol Immunology 2021; 5 (1): 154-175 10.26502/ami.93650055 Original Article Revisiting a Meta-analysis Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19 patients Valère Lounnas1, Alexis Lacout2*, Xavier Azalbert3, Christian Perronne4 1 EMBL Heidelberg alumni, Meyerhofstraße 1, 69117, Heidelberg, Germany 2 Centre de diagnostic ELSAN, Centre médico –chirurgical, Aurillac, France 3 Toulouse School of Economics, 1988 Econometrics, France 4 Service des Maladies Infectieuses et Tropicales, University of Versailles Saint Quentin – Paris Saclay, University Hospital Raymond Poincaré, Garches, France *Corresponding Author: Alexis Lacout, Centre de diagnostic ELSAN, Centre Médico–Chirurgical, 83 avenue Charles de Gaulle, 15000, Aurillac, France, Tel: +33 687273707, Fax: +33 471485348; E-mail: lacout.alexis@orange.fr Received: 22 January 2021; Accepted: 02 February 2021; Published: 09 February 2021 Citation: Valère Lounnas, Alexis Lacout, Xavier Azalbert, Christian Perronne. Revisiting a Meta-analysis Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19 patients. Archives of Microbiology & Immunology 5 (2021): 154-175. Abstract regarding the toxicity of the association HCQ plus Objective: To analyze the impact of study AZI is made. selection on the results of a recently published of Results: Meta-analyses performed on the 11 and studies we deem critically unbiased show a hydroxychloroquine plus azithromycin (AZI) in mortality reduction of 55% for HCQ and 66% for Covid-19 patients. HCQ plus AZI. Methods: 31 studies were reviewed looking for For both treatments, our meta-analysis indicates a critical significant efficacy in reducing mortality in meta-analysis of the hydroxychloroquine bias. Combined efficacy (HCQ) hazard ratios and confidence intervals were calculated for both hospitalized Covid-19 patients. treatments using a fixed effects size model and a random effects model. Quantitative Archives of Microbiology & Immunology analysis Vol. 5 No. 1 – March 2021 154 Arch Microbiol Immunology 2021; 5 (1): 154-175 10.26502/ami.93650055 Keywords: Covid-19; Meta-analysis; Critical they rely blindly on their calculations to firmly bias; suggest that: (1) HCQ alone does not show efficacy Clinical studies; Hydroxychloroquine; against Covid-19; and (2) any patient treated by Azithromycin HCQ and AZI, at any stage of the disease, would 1. develop a high risk of cardiac failure subsequent to
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit